Yearly Registered Patients
ABOUT US
Jamila Sultana Foundation was founded in 2004. In December 2005, a blood bank was added to this facility.
In 2006, we got registered with the Securities and Exchange Commission of Pakistan.
Jamila Sultana Foundation is a welfare health division of Global Pharmaceutical, Islamabad; which is dealing with treatment and prevention of Thalassaemia, a genetically inherited blood disorder. The treatment of Thalassaemia consists of continuous supply of blood and iron chelating medicine, which is provided free of cost to the patients.
The foundation focuses on providing best available treatment to ensure normal quality life to Thalassaemics. It is emerging as one of the organizations all around the world making great contribution in combating Thalassaemia. The center has registered about more than 500 patients which are increasing day by day and the center has provision of transfusing 10 to 15 patients simultaneously every day under the supervision of a dedicated doctors and friendly staff making a pleasant environment for small children which constitute the majority of the patients.
Apart from providing treatment to the existing Thalassaemics, the center is also aimed to prevent the exhibition of the disorder in the future generations and ultimately eradicate it completely in the future
Emotional Problems among children with Thalassemia in Pakistan
An Intervention Programmer`` by Ms, Hina Psychologist
sahenteahxes
Explore the emotional & behavioral issues e.g. anger, absenteeism from school, lack of motivation for treatment
intervention programme advised including some common issues faced by a thalassemic child.
Implementation of intervention program in JSF for all registered children.
Pre and post intervention assessment to give an idea about the level of improvement in the child.
Second round of assessment session conducted after the implementation phase of intervention
Implementation of different combined techniques to alleviate their symptoms induced because of lifelong thalassemia disease
TOTAL PATIENTS
TOTAL HEALTHY PATIENTS
TOTAL VOLUTEERS
PROFESSIONAL AWARDS
TESTIMONIALS
OUR PATIENTS REVIEWS
I have received numerous blood and platelets transfusions under supervision of experts and professionals. The Blood i received was free from any kind of health risks!Umm e Rabia
Thalassemia Patient
I have received numerous blood and platelets transfusions under supervision of experts and professionals. The Blood i received was free from any kind of health risks!Zainab Rahim
Thalassemia Patient
I have received numerous blood and platelets transfusions under supervision of experts and professionals. The Blood i received was free from any kind of health risks!Hina Wajid
Thalassemia Patient
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincid unt ut laoreet dolore magna aliquam eratNimra Jawaid
Thalassemia Patient
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincid unt ut laoreet dolore magna aliquam eratIrsa Shahid
Thalassemia Patient
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincid unt ut laoreet dolore magna aliquam eratMuslim Shah
Thalassemia Patient
Achieving New Heights
Thalassemia Treatment Support to Afghanistan, support 50x Afghani children for the treatment of thalassemia in terms of Medication, Equipment, Technical Support. Financial & Technical support will be identified after approval of MOPH Afghanistan govt, Global Pharmaceutical Pvt Ltd will send team in coordination of NMHRA for implementation phase
Complementary services, extended to carry out Serum Ferritin Test of 400 thalassemic patients ex Holy Family Hospital.
Dr Tanzeel Imran Pathologist JSF, will represent 3 research articles in Thalassemia International Federation (TIF) organized l4th International Conference on Thalassemia & Haemoglobinopathies & l6th TIF International Conference for Patients & Parents in November 2017, Thessaloniki Greece on critical issue and topics relevant to the quality of health, other care, life and safety of the patients. These Researches are for the further improvement of existing laboratory techniques and adaptation to new technology and management options aiming towards the better out come.
New advancement in Haemoglobinopathies, Luspatercept is a fusion protein begins investigated currently for the treatment of thalassemia. The changing face of management, the latest update of ongoing clinical trials will also be discussed in TIF conference November 2017.
IT Department JSF, introducing new IT department to adopt modern trends. Complete automation of JSF through newly developed thalassemia treatment/ prevention software/ to deal with the menace more effectively alongwith launching of new JSF website https:/ /jsf.org. pk
Capacity Building, Capacity of Blood Transfusion Department enhanced from 20-30 heds for daily transfusions. Complete Renovation of JSF infrastructure including installation of new ACs. Installation of Multimedia/ Sound System in BTR to display Videos for awareness/ entertainment of patients during transfusion process. Up gradation/ complete overhaul of transport including Ambulances.
JSF Internship ”Humanity First”, Internship / social work opportunities at JSF platform for fresh qualified students in collaboration with universities to groorrr them as good human being and useful part of society.
launching of computer literacy/Professional Training Programme, impart professional training to thalassemic patients so that they could be part of main stream/ earn their livelihood as normal/ useful independent ciazen. All expenses on computer training will be born by JSF.
Recent Comments